Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review

ISSN: 1875-533X (Online)
ISSN: 0929-8673 (Print)

Volume 22, 38 Issues, 2015

Download PDF Flyer

Current Medicinal Chemistry

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 6th of 59 in Chemistry & Medicinal
  • 47th of 254 in Pharmacology & Pharmacy
  • 81st of 289 in Biochemistry & Molecular Biology

Submit Abstracts Online Submit Manuscripts Online

Atta-ur-Rahman, FRS
Honorary Life Fellow
Kings College
University of Cambridge

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.853
5 - Year: 4.115

Select Language (选择语言):

Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review

Current Medicinal Chemistry, 21(30): 3419-3454.

Author(s): Jose Manuel Calderon-Montano, Estefania Burgos-Moron, Manuel Luis Orta and Miguel Lopez-Lazaro

Affiliation: Department of Pharmacology, Faculty of Pharmacy, University of Seville, C/ Profesor Garcia Gonzalez, 41012, Sevilla, Spain.


Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.


Anticancer, chemotherapy, DNA damage, DNA damage response.

Purchase Online Order Reprints Order Eprints Rights and Permissions


Article Details

Volume: 21
Issue Number: 30
First Page: 3419
Last Page: 3454
Page Count: 36
DOI: 10.2174/0929867321666140601203816

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2015 Bentham Science